A Pilot Evaluation of Refractive Error Progression in Pre-Myopic Children in Singapore With and Without Myopia Control Spectacles
Key facts
- Who runs it
- Singapore National Eye Centre
- Where
- Singapore1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 124 people, planned
- Started
- Aug 2026
- Expected to end
- Feb 2029
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Zeiss MyoActive lenses
- Single Vision Lenses
- Record updated
- 21 August 2026
Who can take part
- Age
- 6 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Participants enrolled in the trial must:
- be accompanied by a parent or guardian who is able to read and comprehend English and sign a record of informed consent/assent
- be able to understand and participate in the Assent process
- at baseline, be within the age range of 6 to 12 years old inclusive
- No prior spectacle correction
- Cycloplegic spherical equivalent (SE) 0.00 to + 2.00 D
- Astigmatism of less than -1.50D
- Anisometropia of not more than 1.50D
- At least 1 parent or more with myopia
Who cannot take part
- Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology in an adverse or beneficial manner at enrolment and/or during the study. NB: Systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the study product is used
- Any concomitant myopia control treatment including atropine eyedrops, contact lenses or other myopia control glasses; The Investigator may, at their discretion, exclude anyone who they believe may not be able to fulfil the study requirements or it is believed to be in the participant's best interests
- Any pre-existing systemic or ocular condition, including infection or disease that is likely to affect visual acuity and refractive error
- Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus
- History of eye trauma
- History of any form of optical correction
- Participants enrolled in the trial must NOT have:
- Amblyopia
- Strabismus
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 12 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to find out whether ZEISS MyoActive lenses can help prevent short-sightedness from developing in children. We aim to recruit at least 50 children in total for this study.
Read full original descriptionShow less
Myopia (short-sightedness) is becoming increasingly common in children worldwide. Early onset of myopia often leads to faster progression and a higher chance of developing high myopia, which increases the risk of serious eye conditions that can affect vision in adulthood, such as retinal detachment, glaucoma, and cataracts. Current treatments can slow the worsening of short-sightedness once children become myopic, but there is limited evidence on whether early intervention can delay myopia from developing in the first place.
This study will compare two types of commonly used spectacle lenses:
ZEISS MyoActive lenses, which are designed to provide a type of optical signal that may reduce the worsening of short-sightedness; and Standard single-vision lenses, which are the usual lenses prescribed for clear vision.
Children who join the study will be randomly assigned to wear one of these two lens types for 12 months. They will attend regular check-ups during this time so we can monitor their eye health and vision.
By randomly assigning children to one of these two lens types and following them over 12 months, we aim to determine whether ZEISS MyoActive lenses:
reduce the likelihood of developing short-sightedness, slow changes in how short-sighted a child's eyes are becoming and eye growth, and are safe, comfortable, and well-tolerated for everyday use. The findings from this study may help improve early myopia prevention strategies and potentially reduce future risks of high myopia and its associated eye conditions.
The 2 groups in the trial
- PlaceboSham treatment, for comparison
Participants will be provided with a pair of spectacles fitted with plano single vision lenses according to the assigned study intervention.
Treatment: Single Vision Lenses
- Zeiss MyoActive LensesTreatment being tested
Participants will be provided with a pair of spectacles fitted with plano MyoActive lenses according to the assigned study intervention.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07779941, who can take part
- Record updated
- 21 August 2026